We are a privately held pharmaceutical company focused on the development and commercialization of JATENZO®, our oral testosterone (T) replacement product. Once approved by the Food and Drug Administration (FDA), JATENZO will be a new T-replacement therapy in the United States as the first oral formulation of a T prodrug, namely, T undecanoate (TU).
Based on our clinical results to date, we believe JATENZO restores circulating T to normal levels and overcome the safety challenges, such as liver toxicity, historically associated with oral T-replacement therapies.
Our investors are Thomas, McNerney & Partners, L.P., H.I.G. BioHealth Partners, ProQuest Investments, C-Bridge Capital Partners, LLC, BVCF Management, Ltd. and Pavilion Capital Pte Ltd.